1. Home
  2. PRAX vs ALKS Comparison

PRAX vs ALKS Comparison

Compare PRAX & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$259.15

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo Alkermes plc

ALKS

Alkermes plc

HOLD

Current Price

$43.20

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
ALKS
Founded
2015
1987
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.7B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
PRAX
ALKS
Price
$259.15
$43.20
Analyst Decision
Strong Buy
Buy
Analyst Count
21
20
Target Price
★ $650.00
$56.21
AVG Volume (30 Days)
498.9K
★ 2.1M
Earning Date
11-04-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,475,899,000.00
Revenue This Year
N/A
$23.54
Revenue Next Year
$39,256.17
$6.53
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$154.46
$27.00
52 Week High
$392.70
$55.67

Technical Indicators

Market Signals
Indicator
PRAX
ALKS
Relative Strength Index (RSI) 38.80 50.91
Support Level $238.77 $39.84
Resistance Level $356.02 $43.22
Average True Range (ATR) 12.63 1.21
MACD -0.52 0.32
Stochastic Oscillator 35.55 81.72

Price Performance

Historical Comparison
PRAX
ALKS

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: